company background image
MDR

MedAdvisorASX:MDR Stock Report

Market Cap

AU$124.6m

7D

10.0%

1Y

-18.5%

Updated

21 Oct, 2021

Data

Company Financials
MDR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

MDR Overview

MedAdvisor Limited, together with its subsidiaries, develops and delivers software for personal medication management in Australia, the United States, the United Kingdom, and Asia.

Price History & Performance

Summary of all time highs, changes and price drops for MedAdvisor
Historical stock prices
Current Share PriceAU$0.33
52 Week HighAU$0.23
52 Week LowAU$0.42
Beta0.13
1 Month Change11.86%
3 Month Change8.20%
1 Year Change-18.52%
3 Year Change20.88%
5 Year Change17.86%
Change since IPO-9.34%

Recent News & Updates

Oct 11
Is MedAdvisor (ASX:MDR) A Risky Investment?

Is MedAdvisor (ASX:MDR) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

MDRAU Healthcare ServicesAU Market
7D10.0%1.3%1.5%
1Y-18.5%39.9%21.1%

Return vs Industry: MDR underperformed the Australian Healthcare Services industry which returned 39.9% over the past year.

Return vs Market: MDR underperformed the Australian Market which returned 21.1% over the past year.

Price Volatility

Is MDR's price volatile compared to industry and market?
MDR volatility
MDR Beta0.13
Industry Beta0.50
Market Beta1

Stable Share Price: MDR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: MDR's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010n/aRobert Readhttps://www.medadvisor.com.au

MedAdvisor Limited, together with its subsidiaries, develops and delivers software for personal medication management in Australia, the United States, the United Kingdom, and Asia. The company provides MedAdvisor, a medication and adherence platform that focuses on improving health outcomes by connecting health professionals with their patients using technology and enhancing medication adherence through health programs using mobile and web apps. MedAdvisor Limited was incorporated in 2010 and is headquartered in Camberwell, Australia.

MedAdvisor Fundamentals Summary

How do MedAdvisor's earnings and revenue compare to its market cap?
MDR fundamental statistics
Market CapAU$124.57m
Earnings (TTM)-AU$13.95m
Revenue (TTM)AU$38.77m

3.2x

P/S Ratio

-8.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MDR income statement (TTM)
RevenueAU$38.77m
Cost of RevenueAU$40.91m
Gross Profit-AU$2.14m
ExpensesAU$11.81m
Earnings-AU$13.95m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.037
Gross Margin-5.51%
Net Profit Margin-35.98%
Debt/Equity Ratio13.1%

How did MDR perform over the long term?

See historical performance and comparison

Valuation

Is MedAdvisor undervalued compared to its fair value and its price relative to the market?

2.57x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MDR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MDR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MDR is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.

PE vs Market: MDR is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MDR is good value based on its PB Ratio (2.6x) compared to the AU Healthcare Services industry average (4.2x).


Future Growth

How is MedAdvisor forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

40.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MedAdvisor has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has MedAdvisor performed over the past 5 years?

-30.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MDR is currently unprofitable.

Growing Profit Margin: MDR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDR is unprofitable, and losses have increased over the past 5 years at a rate of 30.9% per year.

Accelerating Growth: Unable to compare MDR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).


Return on Equity

High ROE: MDR has a negative Return on Equity (-29.42%), as it is currently unprofitable.


Financial Health

How is MedAdvisor's financial position?


Financial Position Analysis

Short Term Liabilities: MDR's short term assets (A$21.3M) do not cover its short term liabilities (A$23.3M).

Long Term Liabilities: MDR's short term assets (A$21.3M) exceed its long term liabilities (A$8.8M).


Debt to Equity History and Analysis

Debt Level: MDR's debt to equity ratio (13.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if MDR's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MDR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27% each year


Dividend

What is MedAdvisor current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Robert Read

5.92yrs

Tenure

AU$739,277

Compensation

Mr. Robert Read, BComm(Mgt), BA(Psych), GAICD., has been the Chief Executive Officer of MedAdvisor Limited since November 12, 2015 and also serves as its Managing Director. Mr. Read served as Managing Dire...


CEO Compensation Analysis

Compensation vs Market: Robert's total compensation ($USD553.64K) is above average for companies of similar size in the Australian market ($USD303.55K).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MDR's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: MDR's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.2%.


Top Shareholders

Company Information

MedAdvisor Limited's employee growth, exchange listings and data sources


Key Information

  • Name: MedAdvisor Limited
  • Ticker: MDR
  • Exchange: ASX
  • Founded: 2010
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$124.567m
  • Shares outstanding: 377.48m
  • Website: https://www.medadvisor.com.au

Location

  • MedAdvisor Limited
  • 971 Burke Road
  • Level 2
  • Camberwell
  • Victoria
  • 3124
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 18:20
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.